Palmoplantar pustulosis (PPP) is a rare chronic inflammatory skin disease mainly affects the soles and palms. The estimated prevalence of palmoplantar pustulosis ranges from 0.01 to 0.05%.Several ... Palmoplantar Pustulosis Market has been evolving and changing over the course of past few decades and the market scope has changed a lot over the course of time and to better understand the market’s ...

Understanding the Context

Monthly Prescribing Reference: Sonelokimab Receives FDA Fast Track Status for Palmoplantar Pustulosis The American Journal of Managed Care: Review Finds Several Biologics Effective in Treating Form of Palmoplantar Psoriasis A systematic review of biologics used in to treat palmoplantar psoriasis and palmoplantar pustulosis, 2 diseases that affect the palms and the soles of feet, found several available biologics are at ... The American Journal of Managed Care: Overlapping Comorbidity Risks Found in Patients With Plaque Psoriasis, Palmoplantar Pustulosis An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups. Patients ... MarketWatch: MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day